MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-18-2026
XOMA Corporation Operating Expenses 2011-2026 | XOMA
Annual Operating Expenses XOMA Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 40.8 M | 68.5 M | 46.6 M | 23.4 M | 20.6 M | 17 K | 22.3 M | 20.2 M | 32.2 M | 62.6 M | 91.5 M | 101 M | 93.3 M | 85.2 M | 92.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 101 M | 17 K | 53.3 M |
Quarterly Operating Expenses XOMA Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.7 M | 8.53 M | 9.98 M | - | 22.8 M | 21.2 M | 8.49 M | - | 6.62 M | 7.62 M | 10.6 M | - | 4.82 M | 5.75 M | 5.17 M | - | 4.28 M | 3.96 M | 6.8 M | 3.71 M | 3.25 M | 3.6 M | 6.42 M | 4.42 M | 5.96 M | 5.67 M | 6.2 M | 4.56 M | 6.2 M | 5.25 M | 5.6 M | 7.37 M | 7.56 M | 8.12 M | 9.16 M | 13.4 M | 12.7 M | 18.5 M | 17.9 M | 18.3 M | 23.2 M | 24.8 M | 25.2 M | 23.5 M | 25.6 M | 24.8 M | 26.8 M | 28.1 M | 23.5 M | 21.2 M | 20.8 M | 20 M | 23.4 M | 22.8 M | 24.2 M | 21.9 M | 23.1 M | 24.4 M | 22.7 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 28.1 M | 3.25 M | 13.8 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Anika Therapeutics
ANIK
|
51.6 M | $ 14.93 | 0.88 % | $ 219 M |  USA |
 |
Aptorum Group Limited
APM
|
20.7 M | $ 0.93 | 0.51 % | $ 5.07 M |  China |
 |
Aquestive Therapeutics
AQST
|
85.5 M | $ 4.14 | 0.36 % | $ 443 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
158 M | $ 8.39 | 4.5 % | $ 230 M |  Israel |
 |
Ardelyx
ARDX
|
95.9 M | $ 6.06 | 1.94 % | $ 1.46 B | USA |
 |
argenx SE
ARGX
|
3.19 B | $ 749.68 | 0.44 % | $ 25 B |  Niderland |
 |
Arcutis Biotherapeutics
ARQT
|
137 M | $ 23.93 | 1.27 % | $ 3.04 B | USA |
 |
Arvinas
ARVN
|
381 M | $ 11.36 | 4.7 % | $ 805 M | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | China |
 |
Arrowhead Pharmaceuticals
ARWR
|
731 M | $ 61.99 | 1.57 % | $ 8.29 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
Assembly Biosciences
ASMB
|
84.4 M | $ 29.09 | 0.28 % | $ 326 M | USA |
 |
Actinium Pharmaceuticals
ATNM
|
36.3 M | $ 1.13 | 15.26 % | $ 35.3 M | USA |
 |
Atossa Therapeutics
ATOS
|
37.1 M | $ 5.19 | -3.36 % | $ 44.7 M | USA |
 |
Atara Biotherapeutics
ATRA
|
361 M | $ 5.0 | 0.2 % | $ 62.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
43.9 M | $ 16.05 | 2.79 % | $ 2.16 B |  Canada |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.41 | -0.35 % | $ 375 M | Britain |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Axon Enterprise
AXON
|
1.18 B | $ 411.97 | -0.2 % | $ 31.2 B | USA |
 |
Aytu BioScience
AYTU
|
53.7 M | $ 2.65 | -1.12 % | $ 16.6 M | USA |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
BioCardia
BCDA
|
15.7 M | $ 1.18 | -1.67 % | $ 7.87 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
144 M | $ 9.59 | 6.26 % | $ 1.98 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
50.6 M | - | 10.36 % | $ 9.8 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
51.4 M | $ 3.05 | 1.51 % | $ 260 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
1.07 B | $ 9.46 | -3.47 % | $ 612 M | USA |
 |
BioVie
BIVI
|
18.1 M | $ 1.46 | 2.81 % | $ 2.16 M | USA |
 |
BioLineRx Ltd.
BLRX
|
28.1 M | $ 2.32 | 4.98 % | $ 908 M | Israel |
 |
BioMarin Pharmaceutical
BMRN
|
1.47 B | $ 56.04 | 0.96 % | $ 10.7 B | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 91.64 | 0.5 % | $ 27.2 B | Germany |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioXcel Therapeutics
BTAI
|
107 M | $ 1.18 | -0.42 % | $ 14.4 M | USA |
 |
Burford Capital Limited
BUR
|
106 M | $ 4.5 | 8.57 % | $ 683 M | Britain |